Sientra to Present at the Canaccord 40th Annual Growth Conference
Sientra, a medical aesthetics company, will participate in the virtual Canaccord 40th Annual Growth Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sientra, a medical aesthetics company, will participate in the virtual Canaccord 40th Annual Growth Conference. The presentation is scheduled for August 13, 2020, at 4:00 p.m. EDT. An audio webcast will be accessible on Sientra's investor relations website, with a replay available for 90 days. Based in Santa Barbara, California, Sientra offers innovative medical aesthetics products, including advanced breast implants and the miraDry system for permanent underarm sweat reduction.
Details
News Market Reaction – SIEN
The recorded move for SIEN in the trading session of this news was +4.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA BARBARA, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today the company will be participating in the upcoming virtual Canaccord 40th Annual Growth Conference. Sientra’s management team is scheduled to present on Thursday, August 13, 2020 at 4:00 p.m. EDT.
Event: Canaccord 40th Annual Growth Conference
Date: Thursday, August 13, 2020
Time: 4:00 p.m. EDT
An audio webcast of the Company’s presentation will be made available on the investor relations section of Sientra’s website at http://www.sientra.com. A replay will be available for 90 days.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS® breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file
Contact
Investor Relations
805-679-8885
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.